甲状腺髓样癌中PET显像:是否应重新评估?
本文聚焦PET显像在甲状腺髓样癌(MTC)三种常见临床场景中的价值:初次甲状腺切除术前、持续/复发疾病颈清扫术前及转移病例随访。文章指出2020年EANM指南推荐对持续性疾病患者行18F-FDOPA PET/CT,而2015年ATA修订版未作此推荐;18F-FDG PET/CT限于侵袭性类型,68Ga-生长抑素类似物PET显像似乎欠佳。
要点
- 2020年EANM指南推荐持续性疾病MTC患者行18F-FDOPA PET/CT。
- 2015年ATA修订版未推荐18F-FDOPA PET/CT。
- 18F-FDG PET/CT仅限侵袭性MTC,68Ga-生长抑素类似物PET显像似乎欠佳。
核心结论
- 本文重新评估PET显像在MTC三个常见临床场景中的临床价值。
研究设计与样本
- 本文为特别文章,聚焦PET显像在MTC三种常见临床场景中的临床价值。
主要发现
- 2020年EANM指南推荐对持续性疾病MTC患者行18F-FDOPA PET/CT。
- 2015年ATA修订版未作出18F-FDOPA PET/CT推荐。
- 18F-FDG PET/CT限于侵袭性类型,68Ga-生长抑素类似物PET显像似乎欠佳。
关键数值与推荐
- 2020年EANM指南推荐对持续性疾病MTC患者行18F-FDOPA PET/CT。
- 2015年ATA修订版未推荐18F-FDOPA PET/CT。
- 18F-FDG PET/CT限于侵袭性类型。
- 68Ga-生长抑素类似物PET显像似乎欠佳。
临床怎么用
- 对持续性疾病MTC患者可考虑18F-FDOPA PET/CT。
- 18F-FDG PET/CT用于侵袭性MTC。
- 68Ga-生长抑素类似物PET显像在MTC中似乎欠佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medullary thyroid carcinomas (MTC) are rare neoplasms derived from calcitonin-secreting cells of the thyroid. They can occur sporadically or as part of the multiple endocrine neoplasia type 2 syndromes. Overall, successful management of MTC patients heavily relies on the patient's conditions, tumor stage, genetic background, and the medical team's experience. Over the past 10 years, many consensus or near consensus of expert panels have been published for the treatment and follow-up of MTC (e.g., American Thyroid Association [ATA] 2009, ATA 2015, European Society of Medical Oncology [ESMO] 2019, European Association of Nuclear Medicine [EANM] 2020). The recent 2020 EANM guidelines recommend in particular to carry out 18F-FDOPA (6-18F-fluoro-L-3,4-dihydroxyphenylalanine) positron emission tomography/computed tomography scan (PET/CT scan) in MTC patients with persistent disease; however, this recommendation was not made in the 2015 ATA revised version. 18F-flurodeoxy glucose PET/CT scan is limited to aggressive forms, and PET imaging using 68Ga-somatostatin analogs appears suboptimal. This special article focuses on the clinical value of PET imaging in three common clinical scenarios (before initial thyroidectomy, before cervical reoperations for persistent/recurrent disease, and in the follow-up of metastatic cases).
引用
- Castinetti F, Taïeb D. Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal? Thyroid. 2020. PMID: 33191866. doi:10.1089/thy.2020.0674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。